Pharmacia & Upjohn

Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President

Retrieved on: 
Monday, February 12, 2024
Cornell University, Acquisition, SAN, Sunovion, Merck, Research, Pharmacia & Upjohn, MD, Drug development, Growth, Research and development, University, Ōtsuka, Therapy, Advanz Pharma, Psychiatry, Development, Cell, Medical research, Pharmaceutical industry

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.

Key Points: 
  • Dr. Corrigan brings over three decades of life sciences leadership experience to Silver Creek.
  • SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.
  • "We are pleased to welcome Dr. Corrigan to lead Silver Creek through its next phase of growth," said Tim Throsby, Silver Creek's Chairman of the Board.
  • "The elegance and innovation behind Silver Creek's Smart Growth Factor™ platform is very compelling, and the pre-clinical data around scp776 is equally impressive.

Bryan Hanson Named CEO of 3M's Health Care Business Group

Retrieved on: 
Tuesday, August 22, 2023
Minimally invasive procedure, Walgreens Boots Alliance, Massachusetts College of Liberal Arts, Medical device, Senior, Pharmacia, Surgery, Information technology, Zimmer Biomet, Culture, Schering-Plough, Women's Health Care Nurse Practitioner-Board Certified, Roman, Pharmacia & Upjohn, Bristol Myers Squibb, Sale, Cox, Cardinal Health, Patient, Health care, Texas Instruments, Outline of health sciences, Seattle Mariners, Growth, Medtech, NYSE, Management, Pharmaceutical industry, Nursing, AmeriCares, Medtronic, Novartis, Covidien

Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.

Key Points: 
  • Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.
  • 3M's Health Care Business Group, with $8.4 billion in sales in 2022, is a diversified health care technology leader with a deep and diverse portfolio of trusted brands, global capabilities, and leadership in attractive end market segments such as wound care, oral care, health care IT, and biopharma filtration.
  • As a standalone business, Health Care will be well-positioned to deliver industry-leading innovation that enables better, smarter, and safer health care for patients worldwide.
  • "I am honored and excited to join 3M's Health Care Business Group at such an important time in its evolution," said Hanson.

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Intercept, Bachelor, Drug development, Therapy, Senior, Pharmacia, Virology, Biotechnology, ATCC, Viral, Pharmacia & Upjohn, ATCC (company), Doctor of Philosophy, Chemistry, Development, HBV, Management, Arbutus

“We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.

Key Points: 
  • “We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.
  • She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC).
  • Dr. Rewolinski, commented, “This is an exciting time to join the Board of Arbutus.
  • I look forward to working with my fellow Board members to support Arbutus in its continued efforts to develop treatments for HBV and coronaviruses.”

Wes Bonner Joins DM Clinical Research as Vice President of Strategic Relationships

Retrieved on: 
Tuesday, May 16, 2023
MAGI, Business development, Society, Pharmacia & Upjohn, Bristol Myers Squibb, Congress, Clinical trial, SCRS, Physician, Bonner, Guidelines International Network, Pharmaceutical industry, Sanofi

HOUSTON, May 16, 2023 /PRNewswire/ -- Clinical research industry veteran Wes Bonner has joined DM Clinical Research as Vice President of Strategic Relationships, bringing more than 25 years of experience cultivating physician relationships and building site networks to the growing Houston-headquartered company.

Key Points: 
  • HOUSTON, May 16, 2023 /PRNewswire/ -- Clinical research industry veteran Wes Bonner has joined DM Clinical Research as Vice President of Strategic Relationships, bringing more than 25 years of experience cultivating physician relationships and building site networks to the growing Houston-headquartered company.
  • "We are thrilled to have Wes Bonner join our team," said Mohammad Millwala, CEO & Founder of DM Clinical Research, an integrated national network of study sites.
  • "Wes has extensive experience and relationships in the clinical research industry that will be particularly important as we expand our network with embedded practices in physician offices.
  • "I am extremely excited to have the opportunity to be a part of the DM Clinical Research team," said Bonner.

Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

Retrieved on: 
Monday, April 24, 2023
Cocrystal, University, Pharmaceutical Research and Manufacturers of America, BS, Avon Products, Pharmacia, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Schering-Plough, Pharmacia & Upjohn, Bausch, Medication, International Federation of Pharmaceutical Manufacturers & Associations, Coronavirus Scientific Advisory Board, Pharmacy, Novartis, MBA, Doctor of Philosophy, Bausch & Lomb, WarnerMedia, Organization, Warburg Pincus, Chemical engineering, Monsanto, Harvard Business School, Merck, Imperial College London, COCP, Management

BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.

Key Points: 
  • BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.
  • Mr. Hassan’s distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical companies and leading investment firms.
  • Earlier this month, Cocrystal announced Mr. Hassan’s $2 million investment in the Company through an at-the-market private placement.
  • “It’s an honor to attract such a highly accomplished industry veteran to our Board,” said Roger Kornberg, PhD, Cocrystal Chairman, Chief Scientist and Chairman of the Scientific Advisory Board.

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Retrieved on: 
Thursday, January 5, 2023
AbbVie, Akebia, Nephrology, Abbott, Pain, Biotechnology, Shire (pharmaceutical company), Therapy, Drug development, Divisional Railway Hospital, Golden Rock, Pharmacia & Upjohn, North Shore University Hospital, Inflammation, Health, The Stony Brook School, BANK, Abbott Laboratories, Amgen, Acquisition, G.D. Searle, LLC, Arthritis, State university system, FDA, Laboratory, Pharmacia, Senior, RED, Metabolism, Pharmaceutical industry, Pfizer, Medicine, Biology

RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors.

Key Points: 
  • RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors.
  • "Rita brings extensive drug development experience to Provention Bio across a wide range of therapeutic areas including autoimmune and metabolic diseases," said Wayne Pisano, Chairman of the Board of Provention Bio.
  • Dr. Jain, a board-certified rheumatologist, currently serves as a member of the supervisory board of AM Pharma and previously served on the Board of Directors of ChemoCentryx, Inc. until its acquisition by Amgen.
  • Earlier in her career, Dr. Jain served as a faculty member at North Shore University Hospital in New York.

Nicox Provides Second Quarter 2022 Financial and Business Highlights

Retrieved on: 
Wednesday, July 20, 2022
Mont Blanc, Kepler, Pharmacia & Upjohn, Association, Pharmacia, Compartment, ARVO, Intraocular pressure, IOP, 470, Company, LLC, Euronext Paris, Retina, Research, Ocular hypertension, Doctor of Philosophy, NO, Annual general meeting, Nitric oxide, Allergic conjunctivitis, Journal, Pharma, Vichy, Fluticasone, Latanoprost, Johannes Kepler, Business, COX, Erosion (morphology), Thermes de Saint Gervais Mont-Blanc, COVID-19, Bausch & Lomb, Duane syndrome, Dolomites, R, Association for Research in Vision and Ophthalmology, NCX, Therapy, Marketing, Pharmacology, Patient, Pharmaceutical industry, Fine chemical, Ophthalmology, Glaucoma

Net revenue 0.7 million for second quarter 2022; cash of 31.6 million on June 30, 2022

Key Points: 
  • Net revenue 0.7 million for second quarter 2022; cash of 31.6 million on June 30, 2022
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial and business highlights for second quarter 2022 for Nicox SA and its subsidiaries (the Nicox Group) and updated on key upcoming milestones.
  • Net revenue1 for the second quarter of 2022 was 0.7 million (consisting entirely of net royalty payments).
  • Net revenue1 for the second quarter of 2021 was 0.7 million (including 0.6 million of net royalty payments).
  • Andreas Segerros joined Nicox as Chief Executive Officer on June 1, 2022.

Nicox Announces a New Governance Structure

Retrieved on: 
Monday, May 16, 2022
Kepler, Sanofi, University, Board of directors, D-Company, Duane syndrome, Euronext Paris, European Ophthalmic Pathology Society, HEC, LLC, University Hall (Uppsala University), Master of Science, Andreas, Investment, Allergic conjunctivitis, Therapy, Audit committee, NCX, Organic chemistry, Latanoprost, Board, Ocular hypertension, Founder, Business, Royal institute, Company, Director, COX, Pharmacia, Johannes Kepler, Pharma, HMR, KTH Royal Institute of Technology, MBA, R, Bausch & Lomb, Leadership, Patient, Compartment, Intraocular pressure, Institute of International Finance, Roussel Uclaf, Marketing, Fluticasone, Pharmacia & Upjohn, Glaucoma, Management, Pharmaceutical industry, Fine chemical, Ophthalmology, NicOx

Michele Garufi will remain as Board member of Nicox SA.

Key Points: 
  • Michele Garufi will remain as Board member of Nicox SA.
  • Jean-Franois Labb has served as a member of Nicox Board of Directors since 2010 and has been the Chairman of the Audit Committee of Nicox since 2013.
  • Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Elios Therapeutics Announces the Appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors

Retrieved on: 
Thursday, February 10, 2022
Pharmacia, Sunovion, Industry, Cubist Pharmaceuticals, Growth, American Psychiatric Association, Distinguished Fellow of the British Computer Society, University, Board, Maine Medical Center, Research, Company, Cancer, Therapy, Director, Patient, Psychiatry, Pharmacia & Upjohn, Melanoma, Neoplasm, Nominal interest rate, American, Cornell University, Vaccine, Prunus, Executive, Drug discovery, LLC, Pharmaceutical industry, Elios, Medicine

AUSTIN, Texas, Feb. 10, 2022 /PRNewswire/ --Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced the appointment of Mark H.N.

Key Points: 
  • AUSTIN, Texas, Feb. 10, 2022 /PRNewswire/ --Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced the appointment of Mark H.N.
  • "It is my pleasure to welcome Dr. Corrigan as our new Chairman of the Board," said Buddy Long, chief executive officer of Elios Therapeutics.
  • Dr. Corrigan has served on the Board of Elios Therapeutics (formerly Perseus Holdings USA) since October 2020.
  • Dr. Corrigan has served on the board of directors of Cubist Pharmaceuticals, Avanir, Colucid Pharmaceuticals, Epirus (Chairman), Novelion (Executive Chairman), Nabriva Therapeutics and BlackThorn (Chairman).

ZielBio Appoints Maria Beconi as Chief Science Officer

Retrieved on: 
Thursday, January 20, 2022
Trial of the century, Research, Patient, PARP, Michigan State University, Pharmacia, Abbott Laboratories, Translational Genomics Research Institute, Clinical professor, Mayo Clinic, DPP-IV, CEO, Antibody, PI3K, Mayo Clinic Alix School of Medicine, Leadership, Therapy, Drug development, Oxaliplatin, Multimedia, TGEN, Cancer, Toxicity, Pharmacia & Upjohn, CHDI Foundation, Plectin, Biochemistry, CSP, Acquisition, Pharmaceutical industry, Sitagliptin, Phoenix, Medicine

CHARLOTTESVILLE, Va., Jan. 20, 2022 /PRNewswire/ --ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative ZielFind drug discovery platform, welcomes Maria Beconi, Ph.D., as the company's chief science officer, and Ramesh Ramanathan, M.D., as vice president for clinical development.

Key Points: 
  • CHARLOTTESVILLE, Va., Jan. 20, 2022 /PRNewswire/ --ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative ZielFind drug discovery platform, welcomes Maria Beconi, Ph.D., as the company's chief science officer, and Ramesh Ramanathan, M.D., as vice president for clinical development.
  • With its ZielFind platform, ZielBio identified and validated CSP, revealing it as an actionable disease target.
  • "I am honored to join the impressive and passionate ZielBio team to help advance the ZielFind target discovery platform and our pipeline of additional candidates in development," said Dr. Beconi.
  • ZielBio is a clinical stage biotechnology company that identifies novel disease targets and develops therapeutic interventions to improve patient outcomes.